COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
The Penumbra of ThalidomideAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Peter Lachmann. The Penumbra of Thalidomide It is some fifty years since the thalidomide disaster when several thousand children around the world were born with severe limb defects after their mothers had been given thalidomide as sedative and remedy for morning sickness. Drugs at that time were not required to have been tested for potential effects on the fetus. One consequence of this tragedy was a great enhancement of the processes for licensing new medicines in an attempt to assuage public anxiety that there could ever be another similar disaster; and that there was any risk at all involved in taking a licensed medicine. Where, nevertheless, significant side effects were found it became the practice to sue for damages. In this lecture a case will be argued that these consequences have given rise to possibly an even greater disaster damaging a much larger number of people and threatening ruin to health services everywhere. The huge increase in both the time taken and the cost involved in bringing a new medicine to market is increasing the price of many new medicines to unsupportable levels. It has also lead to the situation where only companies with deep pockets are able to take medicines to market; and even they will do so only for diseases common enough that they can envisage making a profit. The licensing of new medicines therefore requires urgent and wide-ranging reform which will need changes to both national and European legislation. The increasingly wide spread litigation culture for “statistical” harmful effects that involve neither negligence nor other malfeasance also needs to be addressed. The damages incurred lead to a further increase in the price of medicines. Reforms to reduce the cost of medicines would save the NHS far more than the structural changes now before Parliament. But it will no easier to bring them about. This talk is part of the pjl1000's list series. This talk is included in these lists:Note that ex-directory lists are not shown. |
Other listsCamBridgeSens Visiting Scholar Seminars Type the title of a new list hereOther talksPTPmesh: Data Center Network Latency Measurements Using PTP Mandatory Madness: Colonial Psychiatry and British Mandate Palestine, 1920-48 CGHR Practitioner Series: Sharath Srinivasan, Africa's Voices Developing novel methods for interrogating tree ring anatomy for use in modelling carbon sequestration Analytical Ultracentrifugation (AUC) Sustainability of livestock production: water, welfare and woodland Amino acid sensing: the elF2a signalling in the control of biological functions 'Ways of Reading, Looking, and Imagining: Contemporary Fiction and Its Optics' Vision Journal Club: feedforward vs back in figure ground segmentation Cambridge - Corporate Finance Theory Symposium September 2017 - Day 1 SciBar: Sleep, Dreams and Consciousness |